Quick Dispatch:
Your tirzepatide surpass cvot SURPASS-CVOT trial results: Tirzepatide's impact on diabetes and cardiovascular disease | Paramesh Shamanna posted on the topic orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your tirzepatide surpass cvot SURPASS-CVOT trial results: Tirzepatide's impact on diabetes and cardiovascular disease | Paramesh Shamanna posted on the topic ships.
Need Help?
Questions about tirzepatide surpass cvot SURPASS-CVOT trial results: Tirzepatide's impact on diabetes and cardiovascular disease | Paramesh Shamanna posted on the topic, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for tirzepatide surpass cvot SURPASS-CVOT trial results: Tirzepatide's impact on diabetes and cardiovascular disease | Paramesh Shamanna posted on the topic in your area.
Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT
28.75
In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%
21.84
An Observational Study of Cardiovascular Outcomes of Tirzepatide vs Glucagon-Like Peptide-1 Receptor Agonists
25.12
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
23.93
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
20.18
Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice
25.37
Tirzepatide Demonstrates Cardioprotective Effects in SURPASS-CVOT Trial
29.11
